首页 > 最新文献

Personalized Medicine Universe最新文献

英文 中文
Repositioned alpha-1 adrenoceptor blockers as anti-tumor drugs 重新定位α -1肾上腺素受体阻滞剂作为抗肿瘤药物
Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.04.003
Hisao Nagaya , Yusuke U. Nakagawa , Akinobu Gotoh

Purpose

Drug development has often occurred serendipitously, rather than by using rational approaches. Drug repositioning is an approach that can exploit serendipitous features of a licensed drug.

Study selection and results

Drug repositioning has mainly been used to develop anti-tumor drugs. There are two approaches, drug-based and non-drug-based. The drug-based method develops new drugs using information related to drug function, cohort studies, or side effects. This approach identified anti-tumor drugs, including alpha-1 blockers, HIV-1 protease inhibitors, and metformin. On the other hand, the non-drug-based approach aims to identify drugs using drug libraries and an appropriate assay for each disease. This approach is similar to traditional drug development methods.

Discussions and conclusions

Drug repositioning approaches have enabled our group and others to identify novel anti-tumor drugs. Therefore, drug repositioning can be useful in the development of promising anticancer therapies.

药物开发往往是偶然发生的,而不是通过使用合理的方法。药物重新定位是一种可以利用许可药物的偶然特征的方法。研究选择与结果药物重新定位主要用于开发抗肿瘤药物。有两种方法,以药物为基础和以非药物为基础。以药物为基础的方法利用与药物功能、队列研究或副作用相关的信息开发新药。这种方法确定了抗肿瘤药物,包括α -1阻滞剂、HIV-1蛋白酶抑制剂和二甲双胍。另一方面,非基于药物的方法旨在利用药物库和针对每种疾病的适当分析来识别药物。这种方法类似于传统的药物开发方法。药物重新定位方法使我们的团队和其他人能够识别新的抗肿瘤药物。因此,药物重新定位有助于开发有前景的抗癌疗法。
{"title":"Repositioned alpha-1 adrenoceptor blockers as anti-tumor drugs","authors":"Hisao Nagaya ,&nbsp;Yusuke U. Nakagawa ,&nbsp;Akinobu Gotoh","doi":"10.1016/j.pmu.2015.04.003","DOIUrl":"10.1016/j.pmu.2015.04.003","url":null,"abstract":"<div><h3>Purpose</h3><p>Drug<span> development has often occurred serendipitously, rather than by using rational approaches. Drug repositioning is an approach that can exploit serendipitous features of a licensed drug.</span></p></div><div><h3>Study selection and results</h3><p><span>Drug repositioning has mainly been used to develop anti-tumor drugs. There are two approaches, drug-based and non-drug-based. The drug-based method develops new drugs using information related to drug function, cohort studies, or side effects. This approach identified anti-tumor drugs, including alpha-1 blockers, HIV-1 protease inhibitors, and </span>metformin. On the other hand, the non-drug-based approach aims to identify drugs using drug libraries and an appropriate assay for each disease. This approach is similar to traditional drug development methods.</p></div><div><h3>Discussions and conclusions</h3><p>Drug repositioning approaches have enabled our group and others to identify novel anti-tumor drugs. Therefore, drug repositioning can be useful in the development of promising anticancer therapies.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 23-26"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.04.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77952047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protein factors and chemical compounds regulating hypoxic or oxidative stress responses 调节缺氧或氧化应激反应的蛋白质因子和化合物
Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.04.004
Ami Oguro, Yukino Kobayashi, Susumu Imaoka

Purpose

Hypoxia inducible factor-1α (HIF-1α) and NF-E2-related factor-2 (Nrf2) play central roles in intracellular defense against hypoxia and oxidative stress, respectively. The two stresses are common factors in a variety of disorders, including cardiovascular disease and cancer. In addition, the two stresses occur in succession under ischemia-reperfusion in the context of ischemic cardiovascular disease or organ transplantation. Elucidation of the crosstalk between hypoxic response and oxidative stress response will be beneficial for the treatment of these diseases.

Study selection and results

This review focuses on the molecular crosstalk between the two stress responses, and introduces our findings about the protein factors and chemical compounds that regulate HIF-1α and Nrf2. Cellular stress response (CSR) and small Maf protein G (MafG), both of which act in response to oxidative stress, were found to contribute to the stabilization of HIF-1α. Furthermore, Nrf2 was suppressed under hypoxia in a manner independent of Keap1, which is a primary regulatory pathway for Nrf2, and seven in absentia homolog 2 (Siah2) was identified as a new regulator of Nrf2. Siah2 is a ubiquitin ligase of the prolyl hydroxylase domain containing protein (PHD), which contributes to the degradation of HIF-1α, suggesting that Siah2 regulates both hypoxic and oxidative stress responses. This review also introduces the regulation of HIF-1α and Nrf2 by phenolic compound, bisphenol A (BPA).

Conclusions

Hypoxic and oxidative stress responses are regulated by common factors and are closely linked to each other.

目的缺氧诱导因子-1α (HIF-1α)和nf - e2相关因子-2 (Nrf2)分别在细胞内防御缺氧和氧化应激中起核心作用。这两种压力是包括心血管疾病和癌症在内的各种疾病的常见因素。此外,在缺血性心血管疾病或器官移植的情况下,这两种应激在缺血-再灌注时连续发生。阐明缺氧反应和氧化应激反应之间的串扰关系将有助于这些疾病的治疗。本文主要对HIF-1α和Nrf2的分子串扰进行了综述,并介绍了调控HIF-1α和Nrf2的蛋白因子和化合物的研究进展。细胞应激反应(CSR)和小Maf蛋白G (MafG)都参与氧化应激反应,它们有助于HIF-1α的稳定。此外,Nrf2在缺氧条件下以独立于Keap1的方式被抑制,Keap1是Nrf2的主要调控途径,并且7 in absentia同源物2 (Siah2)被鉴定为Nrf2的新调控因子。Siah2是含脯氨酸羟化酶结构域蛋白(PHD)的泛素连接酶,它有助于HIF-1α的降解,这表明Siah2调节缺氧和氧化应激反应。本文还介绍了酚类化合物双酚A (BPA)对HIF-1α和Nrf2的调控作用。结论缺氧应激和氧化应激反应受共同因素调控,且相互密切相关。
{"title":"Protein factors and chemical compounds regulating hypoxic or oxidative stress responses","authors":"Ami Oguro,&nbsp;Yukino Kobayashi,&nbsp;Susumu Imaoka","doi":"10.1016/j.pmu.2015.04.004","DOIUrl":"10.1016/j.pmu.2015.04.004","url":null,"abstract":"<div><h3>Purpose</h3><p><span>Hypoxia inducible factor-1α (HIF-1α) and NF-E2-related factor-2 (Nrf2) play central roles in intracellular defense against hypoxia and </span>oxidative stress<span><span>, respectively. The two stresses are common factors in a variety of disorders, including cardiovascular disease and cancer. In addition, the two stresses occur in succession under ischemia-reperfusion in the context of ischemic cardiovascular disease or organ transplantation. Elucidation of the crosstalk between </span>hypoxic response<span> and oxidative stress response will be beneficial for the treatment of these diseases.</span></span></p></div><div><h3>Study selection and results</h3><p><span><span>This review focuses on the molecular crosstalk between the two stress responses, and introduces our findings about the protein factors and chemical compounds that regulate HIF-1α and Nrf2. Cellular stress response (CSR) and small </span>Maf protein G (MafG), both of which act in response to oxidative stress, were found to contribute to the stabilization of HIF-1α. Furthermore, Nrf2 was suppressed under hypoxia in a manner independent of Keap1, which is a primary regulatory pathway for Nrf2, and seven in absentia homolog 2 (Siah2) was identified as a new regulator of Nrf2. Siah2 is a </span>ubiquitin ligase<span><span> of the prolyl hydroxylase domain containing protein (PHD), which contributes to the degradation of HIF-1α, suggesting that Siah2 regulates both hypoxic and oxidative stress responses. This review also introduces the regulation of HIF-1α and Nrf2 by phenolic compound, </span>bisphenol A (BPA).</span></p></div><div><h3>Conclusions</h3><p>Hypoxic and oxidative stress responses are regulated by common factors and are closely linked to each other.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 27-31"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.04.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79285028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P53 pathway and cancer: From bench to clinic P53通路与癌症:从实验到临床
Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.03.003
Takashi Tokino, Masashi Idogawa, Yasushi Sasaki

Next-generation sequencing has revealed the genomic landscapes of human cancers and has strengthened the claim that TP53 is the most frequently mutated gene in human cancers. In this review, we intend to clarify the molecular mechanisms underlying the tumor suppressive functions of p53 and understand the involvement of the p53 signaling pathway in tumorigenesis. One of the major goals of this review is to guide the development of more effective approaches for reducing cancer prevalence and fatality.

新一代测序揭示了人类癌症的基因组格局,并加强了TP53是人类癌症中最常见的突变基因的说法。在本文中,我们将阐明p53抑制肿瘤功能的分子机制,并了解p53信号通路在肿瘤发生中的作用。本次审查的主要目标之一是指导制定更有效的方法来降低癌症患病率和死亡率。
{"title":"P53 pathway and cancer: From bench to clinic","authors":"Takashi Tokino,&nbsp;Masashi Idogawa,&nbsp;Yasushi Sasaki","doi":"10.1016/j.pmu.2015.03.003","DOIUrl":"10.1016/j.pmu.2015.03.003","url":null,"abstract":"<div><p>Next-generation sequencing has revealed the genomic landscapes of human cancers and has strengthened the claim that <em>TP53</em> is the most frequently mutated gene in human cancers. In this review, we intend to clarify the molecular mechanisms underlying the tumor suppressive functions of p53 and understand the involvement of the p53 signaling pathway in tumorigenesis. One of the major goals of this review is to guide the development of more effective approaches for reducing cancer prevalence and fatality.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 1-3"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.03.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77195827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Hybrid ensemble learning technique for screening of cervical cancer using Papanicolaou smear image analysis 巴氏涂片图像分析用于宫颈癌筛查的混合集成学习技术
Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2014.10.001
Abid Sarwar , Vinod Sharma , Rajeev Gupta

Objective

This paper presents an innovative idea of applying a hybrid ensemble technique i.e. ensemble of ensemble methods for improving the predictive performance of Artificial intelligence based system for screening of cervical cancer by characterization and classification of Pap smear images.

Methodology

Papanicolaou smear (also referred to as Pap smear) is a microscopic examination of samples of human cells scraped from the lower, narrow part of the uterus, called the cervix. A sample of cells after being stained by using Papanicolaou method is analyzed under microscope for the presence of any unusual developments indicating any precancerous and potentially precancerous changes. Abnormal findings, if observed are subjected to further precise diagnostic subroutines. Examining the cell images for abnormalities in the cervix provides grounds for provision of prompt action and thus reducing incidence and deaths from cervical cancer. It is the most popular technique used for screening of cervical cancer. Pap smear test, if done with a regular screening programs and proper follow-up, can reduce cervical cancer mortality by up to 80% [1]. The contribution of this paper is that we have pioneered to apply hybrid ensemble technique to screen cervical cancer by classification of Pap smear data. The hybrid ensemble designed in this work has also presented an idea to use an ensemble of ensemble techniques. Using such a technique, the classification potentials of individual algorithms are fused together to gain greater classification accuracy. In addition to this we have also presented a comparative analysis of various artificial intelligence based algorithms for screening of cervical cancer.

Results

The results indicate that hybrid ensemble technique is an efficient method for classification of Pap smear images and hence can be effectively used for diagnosis of cervical cancer. Among all the algorithms implemented, the hybrid ensemble approach outperformed & expressed an efficiency of about 96% for 2-class problem and about 78% for 7-class problem. The results when compared with the all the standalone classifiers were significantly better for both 2-class and 7-class problems.

目的提出了一种应用混合集成技术的创新思路,即集成方法的集成,以提高基于人工智能的子宫颈抹片图像特征和分类筛查系统的预测性能。方法帕氏涂片(也称为巴氏涂片)是一种显微镜检查,从子宫较低的狭窄部分(称为子宫颈)刮取人体细胞样本。用Papanicolaou法染色后的细胞样本在显微镜下分析是否存在任何异常的发展,表明任何癌前和潜在的癌前变化。异常的发现,如果观察到,受到进一步的精确诊断子程序。检查子宫颈细胞图像是否有异常,可为采取迅速行动提供依据,从而减少子宫颈癌的发病率和死亡率。这是筛查子宫颈癌最常用的方法。如果定期进行子宫颈抹片检查并进行适当的随访,可将宫颈癌死亡率降低80%[1]。本文的贡献在于,我们率先应用混合集合技术通过子宫颈抹片数据分类来筛查宫颈癌。本文设计的混合集成也提出了使用集成技术的集成的思想。使用这种技术,将各个算法的分类潜力融合在一起,以获得更高的分类精度。除此之外,我们还对各种基于人工智能的宫颈癌筛查算法进行了比较分析。结果混合集合技术是一种有效的子宫颈抹片图像分类方法,可有效用于宫颈癌的诊断。在所有实现的算法中,混合集成方法的性能优于&对2类问题的求解效率约为96%,对7类问题的求解效率约为78%。与所有独立分类器相比,结果在2类和7类问题上都明显更好。
{"title":"Hybrid ensemble learning technique for screening of cervical cancer using Papanicolaou smear image analysis","authors":"Abid Sarwar ,&nbsp;Vinod Sharma ,&nbsp;Rajeev Gupta","doi":"10.1016/j.pmu.2014.10.001","DOIUrl":"10.1016/j.pmu.2014.10.001","url":null,"abstract":"<div><h3>Objective</h3><p>This paper presents an innovative idea of applying a hybrid ensemble technique i.e. ensemble of ensemble methods for improving the predictive performance of Artificial intelligence based system for screening of cervical cancer by characterization and classification of Pap smear images.</p></div><div><h3>Methodology</h3><p><span>Papanicolaou smear (also referred to as Pap smear) is a microscopic examination of samples of human cells scraped from the lower, narrow part of the uterus, called the cervix. A sample of cells after being stained by using Papanicolaou method is analyzed under microscope for the presence of any unusual developments indicating any precancerous and potentially precancerous changes. Abnormal findings, if observed are subjected to further precise diagnostic subroutines. Examining the cell images for abnormalities in the cervix provides grounds for provision of prompt action and thus reducing incidence and deaths from cervical cancer. It is the most popular technique used for screening of cervical cancer. Pap smear test, if done with a regular screening programs and proper follow-up, can reduce cervical cancer mortality by up to 80% </span><span>[1]</span>. The contribution of this paper is that we have pioneered to apply hybrid ensemble technique to screen cervical cancer by classification of Pap smear data. The hybrid ensemble designed in this work has also presented an idea to use an ensemble of ensemble techniques. Using such a technique, the classification potentials of individual algorithms are fused together to gain greater classification accuracy. In addition to this we have also presented a comparative analysis of various artificial intelligence based algorithms for screening of cervical cancer.</p></div><div><h3>Results</h3><p>The results indicate that hybrid ensemble technique is an efficient method for classification of Pap smear images and hence can be effectively used for diagnosis of cervical cancer. Among all the algorithms implemented, the hybrid ensemble approach outperformed &amp; expressed an efficiency of about 96% for 2-class problem and about 78% for 7-class problem. The results when compared with the all the standalone classifiers were significantly better for both 2-class and 7-class problems.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 54-62"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2014.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75708473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 40
A patient-centered model of the action of psychotropic drugs 以病人为中心的精神药物作用模型
Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.03.001
Ravi Philip Rajkumar MD

Background

Psychotropic medications are widely used to treat a variety of mental disorders, but a unifying explanation of their modes of action remains obscure.

Objective

To examine the limitations of existing models of psychotropic drug action, and to propose an integrative, patient-oriented model that explains the wide spectrum of actions of psychotropic medications.

Method

The traditional “disease-centered” model of psychotropic action, and its most logical contemporary alternative, the “drug-centered” model – are critically analysed, and their limitations identified. An alternate model, which acknowledges the importance of patient-related factors in determining drug effects is outlined. The two processes involved in this model, and the evidence in its support, are explained at length with reference to specific psychiatric disorders.

Conclusion

The patient-centered model proposed in this paper, though provisional, provides a broad-based, unified framework for understanding the actions of psychotropic drugs, and can enhance clinical practice and research.

精神药物被广泛用于治疗各种精神障碍,但对其作用方式的统一解释仍不清楚。目的探讨现有精神药物作用模型的局限性,提出一种综合的、以患者为导向的精神药物作用模型。方法对精神药物作用的传统“以疾病为中心”模型及其最符合逻辑的当代替代模型“以药物为中心”模型进行批判性分析,并确定其局限性。另一个模型,它承认在决定药物作用的病人相关因素的重要性概述。这两个过程涉及到这个模型,并在其支持的证据,详细解释了参考具体的精神疾病。结论本文提出的以患者为中心的模式虽然是暂时的,但为理解精神药物的作用提供了一个广泛、统一的框架,可以促进临床实践和研究。
{"title":"A patient-centered model of the action of psychotropic drugs","authors":"Ravi Philip Rajkumar MD","doi":"10.1016/j.pmu.2015.03.001","DOIUrl":"10.1016/j.pmu.2015.03.001","url":null,"abstract":"<div><h3>Background</h3><p>Psychotropic medications are widely used to treat a variety of mental disorders, but a unifying explanation of their modes of action remains obscure.</p></div><div><h3>Objective</h3><p>To examine the limitations of existing models of psychotropic drug action, and to propose an integrative, patient-oriented model that explains the wide spectrum of actions of psychotropic medications.</p></div><div><h3>Method</h3><p>The traditional “disease-centered” model of psychotropic action, and its most logical contemporary alternative, the “drug-centered” model – are critically analysed, and their limitations identified. An alternate model, which acknowledges the importance of patient-related factors in determining drug effects is outlined. The two processes involved in this model, and the evidence in its support, are explained at length with reference to specific psychiatric disorders.</p></div><div><h3>Conclusion</h3><p>The patient-centered model proposed in this paper, though provisional, provides a broad-based, unified framework for understanding the actions of psychotropic drugs, and can enhance clinical practice and research.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 46-53"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75130244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Jidabokuippo use in patients with fractures of the extremities Jidabokuippo用于四肢骨折患者
Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2014.10.002
Hajime Nakae MD , Miwa Hebiguchi , Manabu Okuyama

Aims

Jidabokuippo (JDI) is a traditional Japanese medicine used for alleviating contusion-induced swelling and pain. Usually, nonsteroidal anti-inflammatory drugs (NSAIDs) are used for the treatment of swelling and pain associated with fractures of the extremities. However, one disadvantage of NSAIDs use is their potential to cause gastrointestinal problems, even in patients concomitantly treated with anti-ulcer drugs. In this study, we assessed the effectiveness of JDI in patients with fractures of the extremities.

Methods

Fifty patients (15 men and 35 women) with fractures of the extremities were recruited into the study. All participants were treated using non-invasive methods and administered JDI alone within 3 days of injury. The effectiveness of JDI was assessed following administration by evaluating the need for NSAIDs or other medication. In addition, adverse reactions were monitored.

Results

Comorbidities were present in 42% of the study participants. The mean duration of treatment was 9.9 ± 6.7 days (range 1–35 days). Forty-four patients did not require any medication other than JDI, testifying to its effectiveness. Five participants had their medication switched to NSAIDs, and one patient had eppikajutsuto added to the JDI treatment. In summary, 90% of the patients were effectively treated with traditional Japanese medicines. No adverse reactions were observed.

Conclusion

This study suggests that JDI can be used more widely for fractures of the extremities.

目的:JDI是一种传统的日本药物,用于减轻挫伤引起的肿胀和疼痛。通常,非甾体抗炎药(NSAIDs)用于治疗与四肢骨折相关的肿胀和疼痛。然而,使用非甾体抗炎药的一个缺点是它们可能引起胃肠道问题,即使在同时使用抗溃疡药物的患者中也是如此。在这项研究中,我们评估了JDI在四肢骨折患者中的有效性。方法选取50例四肢骨折患者(男15例,女35例)作为研究对象。所有参与者均采用非侵入性方法治疗,并在损伤后3天内单独给予JDI治疗。通过评估非甾体抗炎药或其他药物的需要来评估JDI的有效性。此外,还监测了不良反应。结果42%的研究参与者存在合并症。平均治疗时间9.9±6.7天(1 ~ 35天)。44例患者不需要除JDI以外的任何药物,证明其有效性。五名参与者的药物换成了非甾体抗炎药,一名患者在JDI治疗中添加了eppikajutsuto。综上所述,90%的患者通过中药得到有效治疗。未见不良反应。结论JDI可广泛应用于四肢骨折的治疗。
{"title":"Jidabokuippo use in patients with fractures of the extremities","authors":"Hajime Nakae MD ,&nbsp;Miwa Hebiguchi ,&nbsp;Manabu Okuyama","doi":"10.1016/j.pmu.2014.10.002","DOIUrl":"10.1016/j.pmu.2014.10.002","url":null,"abstract":"<div><h3>Aims</h3><p><span>Jidabokuippo (JDI) is a traditional Japanese medicine used for alleviating contusion-induced swelling and pain. Usually, nonsteroidal anti-inflammatory drugs (NSAIDs) are used for the treatment<span> of swelling and pain associated with fractures of the extremities. However, one disadvantage of NSAIDs use is their potential to cause gastrointestinal problems, even </span></span>in patients concomitantly treated with anti-ulcer drugs. In this study, we assessed the effectiveness of JDI in patients with fractures of the extremities.</p></div><div><h3>Methods</h3><p>Fifty patients (15 men and 35 women) with fractures of the extremities were recruited into the study. All participants were treated using non-invasive methods and administered JDI alone within 3 days of injury. The effectiveness of JDI was assessed following administration by evaluating the need for NSAIDs or other medication. In addition, adverse reactions were monitored.</p></div><div><h3>Results</h3><p>Comorbidities were present in 42% of the study participants. The mean duration of treatment was 9.9 ± 6.7 days (range 1–35 days). Forty-four patients did not require any medication other than JDI, testifying to its effectiveness. Five participants had their medication switched to NSAIDs, and one patient had eppikajutsuto added to the JDI treatment. In summary, 90% of the patients were effectively treated with traditional Japanese medicines. No adverse reactions were observed.</p></div><div><h3>Conclusion</h3><p>This study suggests that JDI can be used more widely for fractures of the extremities.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 66-69"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2014.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80297365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Serum concentrations of diterpenoid alkaloids after oral administration of powdered processed aconite root 口服炮制附子粉末后血清二萜生物碱浓度的变化
Pub Date : 2014-07-01 DOI: 10.1016/J.PMU.2014.04.001
H. Nakae, Y. Fujita, S. Endo
{"title":"Serum concentrations of diterpenoid alkaloids after oral administration of powdered processed aconite root","authors":"H. Nakae, Y. Fujita, S. Endo","doi":"10.1016/J.PMU.2014.04.001","DOIUrl":"https://doi.org/10.1016/J.PMU.2014.04.001","url":null,"abstract":"","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"54 1","pages":"54-56"},"PeriodicalIF":0.0,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80435419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Personalized medicine for bronchial asthma and allergies 针对支气管哮喘和过敏的个体化药物
Pub Date : 2014-07-01 DOI: 10.1016/J.PMU.2014.03.004
N. Kondo, M. Kuwabara, E. Matsui, Hitomi Kodama, M. Kumada, Kuniyo Kondo, Tomiko Nagata, S. Toida, Hiroshi Mishina, J. Iwasaki, Yukari Matsuno, Yayoi Furuta, A. Shinoda, Sumio Yoshizaki, Chie Tanaka, Akiko Akita, K. Taguchi, Kimiko Hirano
{"title":"Personalized medicine for bronchial asthma and allergies","authors":"N. Kondo, M. Kuwabara, E. Matsui, Hitomi Kodama, M. Kumada, Kuniyo Kondo, Tomiko Nagata, S. Toida, Hiroshi Mishina, J. Iwasaki, Yukari Matsuno, Yayoi Furuta, A. Shinoda, Sumio Yoshizaki, Chie Tanaka, Akiko Akita, K. Taguchi, Kimiko Hirano","doi":"10.1016/J.PMU.2014.03.004","DOIUrl":"https://doi.org/10.1016/J.PMU.2014.03.004","url":null,"abstract":"","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"120 1","pages":"11-14"},"PeriodicalIF":0.0,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80716082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Evaluation of the newly synthesized linoleic acid derivative DCP-LA as a potential anti-dementia drug 新合成的亚油酸衍生物DCP-LA作为潜在抗痴呆药物的评价
Pub Date : 2014-07-01 DOI: 10.1016/J.PMU.2014.02.002
T. Nishizaki, T. Kanno, A. Gotoh
{"title":"Evaluation of the newly synthesized linoleic acid derivative DCP-LA as a potential anti-dementia drug","authors":"T. Nishizaki, T. Kanno, A. Gotoh","doi":"10.1016/J.PMU.2014.02.002","DOIUrl":"https://doi.org/10.1016/J.PMU.2014.02.002","url":null,"abstract":"","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"32 1","pages":"28-34"},"PeriodicalIF":0.0,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87294629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The ethics of personalized medicine 个性化医疗的伦理
Pub Date : 2014-07-01 DOI: 10.1016/j.pmu.2014.03.001
Jack Kushner MD, MGA, FACS, FICS, FAANS, HDG

Personalized medicine is that branch of medicine whereby a patient's treatment and prognosis are based on his genes. Recent genetic research explains the variations and similarities between humans, their diseases, and their responses to various treatments. Because governments and universities have not set strict standards, there are numerous tests and kits available to detect genetic problems. But are these kits accurate? The validity of some biomarkers is suspect.

The ethics of personalized medicine became an issue when some laboratory tests resulted in women incorrectly having been told that they have a high risk of breast or ovarian cancer when they did not. Ethical issues are not confined to the utilization of genetic information, but can be raised with the acquisition of human material for the advancement of knowledge. Whose genes are these? Who owns your DNA?

In the US, patients are given prenatal genetic advice upon which they can decide for themselves how to proceed. But in Russia, patients have no choice. The state makes most decisions. Selective breeding would be unacceptable in western countries.

个性化医疗是医学的一个分支,病人的治疗和预后是基于他的基因。最近的基因研究解释了人类之间的差异和相似之处,他们的疾病,以及他们对各种治疗的反应。由于政府和大学没有制定严格的标准,有许多测试和试剂盒可用于检测遗传问题。但是这些工具准确吗?一些生物标记物的有效性值得怀疑。当一些实验室测试导致女性被错误地告知她们患乳腺癌或卵巢癌的风险很高时,个性化医疗的伦理就成了一个问题。伦理问题不仅限于遗传信息的利用,而且可以在获取人类材料以提高知识的过程中提出。这些是谁的基因?谁拥有你的DNA?在美国,患者会得到产前遗传建议,他们可以自行决定如何进行。但在俄罗斯,病人别无选择。国家做出了大部分决定。选择性育种在西方国家是不可接受的。
{"title":"The ethics of personalized medicine","authors":"Jack Kushner MD, MGA, FACS, FICS, FAANS, HDG","doi":"10.1016/j.pmu.2014.03.001","DOIUrl":"10.1016/j.pmu.2014.03.001","url":null,"abstract":"<div><p>Personalized medicine is that branch of medicine whereby a patient's treatment and prognosis are based on his genes. Recent genetic research explains the variations and similarities between humans, their diseases, and their responses to various treatments. Because governments and universities have not set strict standards, there are numerous tests and kits available to detect genetic problems. But are these kits accurate? The validity of some biomarkers is suspect.</p><p>The ethics of personalized medicine became an issue when some laboratory tests resulted in women incorrectly having been told that they have a high risk of breast or ovarian cancer when they did not. Ethical issues are not confined to the utilization of genetic information, but can be raised with the acquisition of human material for the advancement of knowledge. Whose genes are these? Who owns your DNA?</p><p>In the US, patients are given prenatal genetic advice upon which they can decide for themselves how to proceed. But in Russia, patients have no choice. The state makes most decisions. Selective breeding would be unacceptable in western countries.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"3 ","pages":"Pages 42-45"},"PeriodicalIF":0.0,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2014.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88682212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
期刊
Personalized Medicine Universe
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1